deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04599140

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

Phase Ib/II Trial of SX-682 in Combination With Nivolumab for Refractory RAS Mutated (RAS) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1)

Sponsor: Bristol-Myers Squibb

Conditions Metastatic Colon Adenocarcinoma Metastatic Colorectal Carcinoma Metastatic Rectal Adenocarcinoma Stage III Colon Cancer AJCC v8 Stage III Rectal Cancer AJCC v8 Stage IIIA Colon Cancer AJCC v8 Stage IIIA Rectal Cancer AJCC v8 Stage IIIB Colon Cancer AJCC v8 Stage IIIB Rectal Cancer AJCC v8 Stage IIIC Colon Cancer AJCC v8 Stage IIIC Rectal Cancer AJCC v8 Stage IV Colon Cancer AJCC v8 Stage IV Rectal Cancer AJCC v8 Stage IVA Colon Cancer AJCC v8 Stage IVA Rectal Cancer AJCC v8 Stage IVB Colon Cancer AJCC v8 Stage IVB Rectal Cancer AJCC v8 Stage IVC Colon Cancer AJCC v8 Stage IVC Rectal Cancer AJCC v8 Unresectable Colon Adenocarcinoma Unresectable Rectal Adenocarcinoma
Interventions CXCR1/2 Inhibitor SX-682 Nivolumab
Updated 19 times since 2020 Last updated: Jan 20, 2026 Started: Oct 14, 2020 Primary completion: Jul 31, 2026 Completion: Jul 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04599140, this PHASE1/PHASE2 trial focuses on Metastatic Colon Adenocarcinoma and Metastatic Colorectal Carcinoma and remains ongoing. Sponsored by Bristol-Myers Squibb, it has been updated 19 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Jul 2022 · 16 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Aug 2025 · 6 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

19 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Feb 2025 — Aug 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Sep 2024 — Feb 2025 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 14 earlier versions

  1. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

  2. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

  6. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE1_PHASE2

  7. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2022 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2021 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  12. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  14. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • M.D. Anderson Cancer Center
  • Syntrix Biosystems, Inc.
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations